Successful Treatment of T-Cell Prolymphocytic Leukemia with Alemtuzumab
Ueki, D.; Yoshida, C.; Tsutsumi Oota, I.; Seki, M.; Komeno, T.; Ito, H.; Ide, Y.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 46(5): 913-915
2019
ISSN/ISBN: 0385-0684 PMID: 31189814 Document Number: 698073
T-cell prolymphocytic leukemia(T-PLL)is a highly aggressive hematopoietic malignancy with poor prognosis and is extremely rare in Japan. Since T-PLL cells usually express high levels of CD52, the anti-CD52 monoclonal antibody alemtuzumab is expected to exhibit an antitumor effect via its antibody-dependent cell cytotoxicity(ADCC)and complement-dependent cytotoxicity(CDC). However, the therapeutic efficiency of alemtuzumab for T-PLL has not been established in Japan. Furthermore, only a few patients have completed the treatment schedule because of adverse events. Here, we report a 64-yearold woman with multiple comorbidities who was successfully treated with alemtuzumab.